Your Needs
Dealing with a Dilemma
We understand your dilemma: biopharmaceutical manufacturers must honestly characterize product safety risks while preserving market access for patients in need of therapy.
Avoiding "overkill" risk mitigation that unnecessarily burdens health care providers and creating programs that clinicians value and patients can use are key to product success.
Moreover, internal groups have different perspectives. Some groups are charged with facilitating product approval, whereas others are charged with maximizing sales. At times, these objectives may seem in conflict, though patient safety and privacy always come first.
When best practices are coupled with our proprietary risk assessment methodologies, such as RxFMEA®, and our experience designing appropriate interventions, our programs strike the balance that improves product performance and health outcomes.
Wherever your product or portfolio stands in the life cycle, you may be looking for ways to:
- Prioritize and mitigate adverse event risk using state-of-the-art methods
- Collaborate with clinicians to develop tools that minimize risk
- Make it easier for physicians to identify patients most likely to benefit from therapy
- Support the physician/patient therapy partnership with helpful education
- Demonstrate appropriate risk mitigation to regulators
- Help create the post-marketing evidence base for using your therapy
Since few products launch with unquestioned safety, developing programs for risk mitigation and appropriate use could benefit most of the therapies in the pipeline and on the market.
Ask us for a regulatory orientation to help inform your team about the options.